At a glance
- Originator Dainippon Sumitomo Pharma
- Class Anti-ischaemics
- Mechanism of Action Endothelin-converting enzyme 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Renal failure; Reperfusion injury
Most Recent Events
- 08 Feb 2008 Discontinued - Preclinical for Renal failure in Japan (unspecified route)
- 08 Feb 2008 Discontinued - Preclinical for Reperfusion injury in Japan (unspecified route)
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma